RGD4C-AAVP, with its transcriptional- and ligand-directed-targeting features and stable long-term gene expression under the eukaryotic Grp78 promoter, is a promising tool in targeted systemic cancer gene therapy, and should be brought forth in future clinical trials in cancer patients. This evidence concerns the gene HSPA5 and cancer.